Anticancer Bioscience
  • About
    • Management Team
    • Scientific Advisory Board
  • Pipeline
  • Science
    • SYMPLEX
    • Publications
  • News & Events
    • Press Releases
    • In the News
  • Careers
  • Contact

Press release

02 June 2026
Anticancer Bioscience Advances Three Additional MYC Synthetic-Lethal Drug Candidates into IND-Enabling Development

Chengdu, China, June 2, 2026 — Anticancer Bioscience (ACB) announced that three additional MYC synthetic-lethal drug candidates – JMBI-002, JMBI-003, and JMBI-204 – had entered IND-enabling development as of June 2, 2026. These programs expand ACB’s pipeline beyond its lead candidate, JMBI-001.

Discovered through ACB’s proprietary SYMPLEX™ platform, the three candidates have distinct chemical scaffolds and differentiated biological and pharmacological profiles. ACB employed mechanism-informed phenotypic screening (MIPS), a multiparameter phenotypic assay system, to guide their selection and optimization. MIPS evaluates target-proximal cellular defects induced by compound treatment rather than relying solely on inhibitory potency against isolated recombinant target proteins.

IND-enabling development encompasses chemistry, manufacturing, and controls (CMC), pharmacokinetic studies, and nonclinical safety evaluation. ACB plans to submit IND applications for all three candidates in 2027, subject to the successful completion of the required studies.

About Anticancer Bioscience

Anticancer Bioscience (ACB) is a Chengdu-based biotechnology company developing innovative anticancer therapies that exploit cancer-specific dependencies. Its drug-development programs translate discoveries in cancer biology and synthetic lethality into novel therapeutic approaches.


Anticancer Bioscience © 2026
Terms of use
Privacy policy